COVID-19

COVID-19 treatments: under evaluation

The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.

COVID-19 treatments under marketing authorisation evaluation

EMA's CHMP is evaluating marketing authorisation applications (which may be for conditional marketing authorisation) for the following COVID-19 treatments:

TreatmentTreatment developerKey milestonesMore information
Lagevrio (molnupiravir)Merck Sharp & Dohme and Ridgeback Biotherapeutics 

Marketing authorisation evaluation started: 23/11/2021

CHMP negative opinion: 23/02/2023

Re-examination request submitted: 13/03/2023

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023

Withdrawn from marketing authorisation evaluation

Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:

TreatmentTreatment developerKey milestonesMore information
Olumiant (baricitinib)Eli Lilly Nederland B.V.Marketing authorisation evaluation started: 23/11/2021

Withdrawn from marketing authorisation evaluation: 07/12/2022

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022

 

Withdrawn from rolling review

Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:

TreatmentTreatment developerKey milestonesMore information
Bamlanivimab and etesevimabEli LillyRolling review started: 11/03/2021

Withdrawn from rolling review: 29/10/2021
Latest news

Paediatric investigation plan for bamlanivimab

Paediatric investigation plan for etesevimab

Topics

How useful was this page?

Add your rating
Average
11 ratings
1 rating
2 ratings
11 ratings